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Abstract
Background: The evidence-based practice of active surveillance to monitor men with favorable-risk prostate cancer
in lieu of initial definitive treatment is becoming more common. However, there are barriers to effective
implementation, particularly in low-resource settings. Our goal is to assess the efficacy and feasibility of a health
information technology registry for men on active surveillance at a safety-net hospital to ensure patients receive
guideline-recommended care.
Methods: We developed an electronic registry for urology clinic staff to monitor men on active surveillance. The
health information technology tool was developed using the Systems Engineering Initiative for Patient Safety
model and iteratively tailored to the needs of the clinic by engaging providers in a co-design process. We will
enroll all men at Zuckerberg San Francisco General Hospital and Trauma Center who choose active surveillance as a
treatment strategy. The primary outcomes to be assessed during this non-randomized, pragmatic evaluation are
number of days delayed beyond recommended date of follow-up testing, the proportion of men who are lost to
follow-up, the cancer stage at active treatment, and the feasibility and acceptability of the clinic-wide intervention
with clinic staff. Secondary outcomes include appointment adherence within 30 days of the scheduled date.
Discussion: Use of a customized electronic approach for monitoring men on active surveillance could improve
patient outcomes. It may help reduce the number of men lost to follow-up and improve adherence to timely
follow-up testing. Evaluating the adoption and efficacy of a customized registry in a safety-net setting may also
demonstrate feasibility for implementation in diverse clinical contexts.
Trial registration: ClinicalTrials.gov identifier NCT03553732, An Electronic Registry to Improve Adherence to Active
Surveillance Monitoring at a Safety-net Hospital. Registered 11 June 2018.
Keywords: Health information technology (HIT), Active surveillance, Prostate cancer, Systems Engineering Initiative
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Background
Active surveillance (AS) is an increasingly acceptable strat-
egy for treating patients with low- or intermediate-risk
prostate cancer [1]. This management strategy is recom-
mended for men who are likely to experience better or
similar outcomes with careful monitoring and repeated
testing than they would with active treatment, such as rad-
ical prostatectomy or radiation therapy [2]. It begins with
shared decision-making between patients and physicians
before screening, as well as coordination across care
teams. Once selected, AS entails longitudinally following
men with serial blood laboratory testing of prostate-spe-
cific antigen (PSA) levels and prostate tissue biopsies to
monitor for disease progression. If disease progression oc-
curs, patients can transition to active treatment.
However, despite evidence-based recommendations for
AS in the right patient population and increased adoption
as a management strategy, men are still not receiving timely
and consistent monitoring [3, 4]. The vast majority of men
on AS in clinical practice do not receive adequate monitor-
ing according to the National Comprehensive Cancer Net-
work (NCCN) guidelines for monitoring with PSA testing
and prostate biopsy, and even fewer meet the more rigor-
ous standards of clinical trial protocols [5, 6]. In a study by
Luckenbaugh and colleagues, biopsy follow-up was discord-
ant in 54% of men during the first 2 years of AS monitoring
[6]. In another study examining follow-up beyond 2 years,
the number of men who received biopsy declined to <
13% [5]. Clinical trials indicate that a significant proportion
of men on AS may develop more aggressive cancer [7].
Therefore, it is critical that they undergo monitoring so that
progression to more aggressive cancer can be identified and
treated in a timely fashion.
Scrupulous monitoring is even more critical at safety-
net hospitals. Low-income patients and racial and ethnic
minorities are more likely to seek care in safety-net health
care settings where limited resources, including fragmen-
ted health information technology (HIT), and patient
characteristics can introduce additional risks [8, 9]. Al-
though some studies report that African American/Black
men receive the same or slightly fewer follow-up PSA tests
or prostate biopsies than Caucasian men, African Ameri-
cans/Blacks are more likely to experience reclassification
during surveillance and subsequently receive treatment
for their prostate cancer [10, 11]. Krupski et al. demon-
strated that low socioeconomic status was associated with
increased uptake of conservative management [12]. It is
unclear why this population of men receives conservative
management more frequently. Active treatment may be
more costly for uninsured populations, but in this care
setting, cost differences are unlikely to play a role. Prior
work suggests that men of lower socioeconomic status
may be less likely to opt for surgery because of lack of
trust [13]. In another study, loss to follow-up (LTFU) in
AS was significantly higher at a safety-net hospital (57% at
5 years) compared to a university cancer center (37% at 5
years), and low socioeconomic status increased likelihood
of LTFU [14]. Taken together, these findings suggest that
safety-net hospitals serve patients who are more likely to
select AS and also experience LTFU. These factors
increase the risk of undetected progression of prostate
cancer and resultant poor treatment outcomes.
Vulnerabilities in the safety-net population, including
mental health issues, non-English language, homelessness,
substance use, and impaired literacy and numeracy, may
contribute to sub-optimal adherence to AS. Therefore, it
is imperative that we adopt strategies that increase the
likelihood of a successful monitoring practice.
We plan to implement an AS monitoring interven-
tion in the San Francisco Health Network, the city-
funded integrated health care delivery system. The
network is served by a single urology clinic located at
Zuckerberg San Francisco General Hospital (ZSFG)
and staffed by faculty and trainee physicians from the
University of California, San Francisco. ZSFG has
prior data of monitoring on AS from the Osterberg et
al. study for comparison with the intervention [15].
The authors previously reported that 18.3% of the
men on AS at this facility exhibited cancer upgrade
and 17% were LTFU. The current system in place at
the urology clinic utilizes an Excel spreadsheet to
monitor patients on AS. We aim to perform a pilot
study implementing a novel, co-designed HIT plat-
form in an effort to improve the monitoring of and
adherence to the recommended AS guidelines. The
pilot study will test the feasibility, acceptability, and
preliminary estimates of efficacy in utilizing a HIT
tool for AS in the urology clinic at ZSFG. This pilot
is necessary to determine whether the effort to
systematize monitoring for AS improves patient out-
comes. Based on the initial results of primary and
secondary outcomes, we will iterate the platform for
use in the ongoing study.
Methods
Intervention development
To inform this intervention, we used the Systems Engin-
eering Initiative for Patient Safety (SEIPS) model that has
previously been applied in an outpatient surgery context
[16]. SEIPS targets three basic interconnected elements of
a clinic—work system (or organizational structure),
process, and outcome—for potential intervention. We uti-
lized a human factors design approach frequently used
across industries, called journey mapping, to elicit details
from doctors, nurses, nurse practitioners, and other stake-
holders involved in the monitoring process about a
patient’s journey through the outpatient urology clinic
while on active surveillance [17–20]. Journey maps allow
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for identification of steps in the monitoring process that
are particularly vulnerable to gaps in patient safety. From
the journey map, we identified vulnerabilities in patient
safety domains including tasks, technology, organization,
people, and environment [21, 22]. Vulnerabilities included
patient challenges (homelessness, substance abuse, and
mental illness), the cognitive load of tracking patients,
time-limiting factors such as the rotating schedules of resi-
dents, and overall task burden on providers.
In order to develop a viable patient monitoring system,
we used a novel design seed method to address these
vulnerabilities [17, 23, 24]. Design seeds take the place
of the typical technical approach that moves from prob-
lem to solution by serving as a bridge between vulner-
abilities experienced and solution attributes. They serve
as modular and evaluable “seeds” to solutions that pro-
mote early and iterative evaluations before investing in a
full-fledged solution. This process was refined through
multiple iterations with input from providers to produce
a finely tuned tool specific to the needs of the urology
clinic.
Health information technology tool
The electronic monitoring tool was customized for use
in the urology outpatient clinic for men on AS. The top
five design seeds identified in the urology clinic as most
important for improving monitoring and saving time
were as follows: “keeps list up to date,” “customize the
patient list,” “ability to control data access,” “population
registry functionality for high-risk patients,” and “assign
roles and responsibilities” [17]. Based on these results
and other input from medical professionals with know-
ledge of the unique challenges facing the clinic, we
partnered with CipherHealth (New York, NY), a health-
care technology company, to develop a registry to aid in
patient monitoring. This tool consolidates patient infor-
mation from three major data sources and provides cli-
nicians with the ability to track patients on AS to ensure
up-to-date and timely care (Fig. 1). Aside from the auto-
matic feed of data from Openlink, manual data entry by
clinical staff is also possible. The AS registry tracks and
notifies the clinic team when testing is due, according to
the recommended AS protocol (Fig. 2a) [25–27]. This
includes PSA testing every 3 months for the first 1–2
years post-enrollment, PSA every 6 months > 2 years
post-enrollment, 1 confirmatory biopsy within 12
months of enrollment, biopsy every 2 years > 1 year post-
enrollment, follow-up visit every 3–6 months post-en-
rollment, and MRI as needed (Fig. 2b).
Study design
This study is a prospective non-randomized pilot
study that will add newly diagnosed men with pros-
tate cancer who choose AS as an initial management
strategy to the registry and follow them. We will also
continue to track men who are already on AS at
ZSFG, adding them into the new system. Patients will
be entered into the registry by involved healthcare
providers. A team of care managers, including a nurse
practitioner and medical residents, will perform regis-
try enrollment and maintenance. As the team of med-
ical residents rotates, the study group will conduct
recurring training sessions to ensure all users are able
to access and use the tool. In our case, this is ap-
proximately every 4 months. When the residents re-
turn to the urology clinic on rotation, they can
Fig. 1 Workflow diagram depicting the various elements of the HIT tool
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engage in peer-training. The study team and Cipher-
Health provide ongoing support for the clinical staff.
CipherHealth offers a data portal for the study team
to be able to capture real-time metrics, such as num-
ber of patients enrolled, tasks completed, and out-
comes. The registry will provide automated reminders
to prompt follow-up activities (e.g., visits, testing,
check-ins). Eligibility criteria for AS include diagnostic
PSA ≤ 10 ng/ml, clinical stage T1 or T2, Gleason
scores ≤ 3 + 4, ≤ 33% positive cores, and ≤ 50% tumor
in any single core. The frequency and cadence of fol-
low-up tests will be tracked and compared to prede-
termined recommended guidelines. We will monitor
deviations from an established timeline including but
not limited to delayed or missed PSA testing, delayed
or missed prostate biopsy, and LTFU as defined by
no PSA test or prostate biopsy for 18 months at
ZSFG or a participating hospital in the health infor-
mation exchange. We will also record definitive treat-
ment, modality, and reason for changes in
management, as well as patient-related outcomes such
as overall and prostate cancer-specific mortality.
There will be a minimum follow-up period of 2 years
to make baseline inferences about the efficacy and
adoption of the registry, with continuous accrual ex-
tending indefinitely. We will descriptively compare
outcomes from this new cohort of AS patients to the
results from the Osterberg et al. study, including pro-
portion of men LTFU, average number of PSA mea-
surements and prostate biopsies, and time from
diagnosis to active treatment. At this juncture, with 2
years of data and an understanding of how well the
Fig. 2 a Screenshot depicting the population-level view of patients on AS. The patient names are fictitious for demonstration purposes. b
Screenshot of AS follow-up tasks on the patient level
Cedars et al. Pilot and Feasibility Studies           (2019) 5:101 Page 4 of 7
registry has been integrated into clinical workflows,
appropriate adjustments will be implemented for the
continuation of the study.
Patient population
The goal of the study is to enroll all patients in the clinic
who are undergoing AS. There are currently 44 patients
who have been added to the registry; 40 of whom are be-
ing managed by AS. Of the remaining four men, one
began active treatment, one declined further treatment,
and two have transferred care elsewhere. These patients
have been on AS for a median of 3.2 years.
The prior AS study at the ZSFG demonstrated that pa-
tients at the urology clinic had median age at prostate can-
cer diagnosis of 61.5 years (range 44–81 years) [15]. The
racial composition was 29% African American/Black, 25%
White, 30% Asian/Pacific Islander, and 15% Hispanic/La-
tino. Sixty-four percent of men primarily spoke English, 9%
Spanish, 16% Chinese, and 12% other. For all ambulatory
surgery patients at ZSFG, more than two thirds are insured
by Medi-Cal (California’s Medicaid Program) [28].
Medical record review
Patients with confirmed pathologic diagnosis of prostate
cancer seen at least once in the clinic will be eligible for
record review. Data abstraction will include sociodemo-
graphic, clinical, and treatment variables, including age,
race, PSA level at diagnosis, clinical stage, Gleason score,
and treatment modality (Table 1).
Outcomes
Primary outcomes include the number of days delayed
past recommended follow-up interval (continuous vari-
able), proportion of men who are LTFU, cancer stage at
time of active treatment, and clinic team acceptability
and feasibility of the registry tool. Secondary outcomes
include appointment adherence within 30 days (binary)
(Table 2). We will measure the feasibility and acceptabil-
ity of the HIT tool among clinic staff using semi-struc-
tured interviews. We will interview at least one clerk
responsible for scheduling, one registered nurse, one
nurse practitioner, and at least three urologists. We will
not be aiming for a specific proportion of staff, but ra-
ther representation of all types of staff. The interviews
will be conducted once the registry has been in use for
6 months. If staff who have been involved with the sys-
tem leave the team, we will conduct exit interviews to
ensure their voices are included. These interviews will
be based on the principles of perceived usefulness and
ease of use from the technology acceptance model
framework [29]. Among other parameters, this frame-
work investigates usefulness, ease of use, relevance, and
result demonstrability. Using a grounded theory ap-
proach, we will analyze semi-structured interviews
abductively, integrating inductive and deductive reason-
ing to explore and describe emergent themes within
structured domains of interest. Within each domain, we
will iteratively open-code, analyze, and theorize until we
have reached saturation and no more themes emerge. Fi-
nally, we will see if we can integrate themes across do-
mains for a unified theory [30]. Our definition of an
effective intervention is one that limits the delay in re-
ceiving follow-up tests, reduces the number of men
LTFU, and promotes active treatment at lower cancer
stages (e.g., non-metastatic disease), and one that the
clinical team rates highly in terms of feasibility and
acceptability.
Analyses
Descriptive statistics will be used to report patient
demographics, clinical characteristics, and treatment
decisions, with medians and ranges or frequency and
percentages depending on the type of data. Kaplan-
Meier estimates will measure adherence to AS. Multi-
variate logistic regression will predict risk of non-ad-
herence, definitive treatment, biopsy upgrade, and
mortality. Covariates will include age, race, PSA at
diagnosis, Gleason grade, clinical stage, and number
of comorbidities.
Discussion
Active surveillance for men with low-risk prostate cancer
is a safe and effective management strategy. However, this
process occurs over a time period of years and requires
Table 1 Domains for data abstraction from medical records of
patients who enroll in AS
Domain Data element
Demographics Age
Sex
Race/ethnicity
Primary language
Insurance type
Social history History of tobacco use
History of substance abuse
History of homelessness
Employment history
Clinical characteristics PSA at diagnosis
Clinical T-stage
Gleason score
Positive biopsy cores
Treatment modality (if discontinue AS)
Medical history Number of comorbidities
History of mental illness
Family history of prostate cancer
Cedars et al. Pilot and Feasibility Studies           (2019) 5:101 Page 5 of 7
ongoing patient adherence to blood tests, appointments,
and prostate biopsies, which are invasive medical proce-
dures. This complex, long-term follow-up model presents
challenges to adherence and proper delivery of care. The
San Francisco Health Network is a publicly funded health
system with circumscribed clinical personnel, fragmented
electronic health records, and a diverse patient population
that make AS monitoring particularly challenging. Fur-
thermore, one study warned that AS may perform poorly
at identifying African American/Black men with low-risk
prostate cancer based on adverse pathology (i.e., worse
cancer stage or Gleason grade) at radical prostatectomy
[31]. This prospect makes thorough and timely follow-up
essential due to the increased risk of under-staging.
The digital registry system we created will give pro-
viders the ability to track appointments, follow-up tests,
and results. This system is independent from the general
medical record and is therefore unencumbered by the
heterogeneity of paper or various electronic medical rec-
ord systems. The implications of a successful electronic
monitoring system may reach beyond this single institu-
tion. A successful registry tool that can demonstrate bet-
ter adherence to AS and less LTFU could serve as a
template for other urology clinics in resource-con-
strained contexts. In turn, this has the potential to re-
duce disparities in prostate cancer outcomes, because
patients at most risk for poor outcomes are dispropor-
tionately cared for in safety-net settings.
Potential challenges include technical difficulties
with the tool itself, poor adoption of the tool by pro-
viders, or misuse, as well as unforeseen issues. How-
ever, the monitoring system was designed in a theory-
informed manner and tailored to meet the needs and
specifications of the clinic. We expect that the
adapted design approach will enable accelerated adop-
tion and efficacy in monitoring men with prostate
cancer and thereby improve patient outcomes.
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